Outcome of Acute Kidney Injury in Critical Care Unit, Based on AKI Network

Seyed Mohammadreza Hashemian 1, Hamidreza Jamaati 2, Behrooz Farzanegan Bidgoi 1, Farin Rashid Farrokhi 3, Majid Malek Mohammad 4, Sepehr Roozdar 1, Seyed Amir Mohajerani 1, Ahmad Bagheri 1, Golnar Radmmand 1, Behzad Hatami 1, Mandana Chitsazan 1

1 Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2 Tobacco Prevention and Control Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3 Telemedicine Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4 Tracheal Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran

INTRODUCTION

Acute Kidney Injury continues to remain a significant problem in hospitalized patients and has a high mortality rate. Furthermore, the incidence of AKI continues to increase and currently there is no definitive therapy for it (1). It is a complex functional or structural disorder, which occurs abruptly, usually within 48 hours of hospitalization and is defined as a sudden onset of reduced kidney function (2). Previous studies highlight the importance of early recognition of AKI as well as the association of AKI with increased mortality in hospitalized patients (3). The clinical spectrum of AKI ranges from slight elevations in serum creatinine to anuric renal failure. Acute kidney injury causes disturbances in fluid balance, electrolytes, and acid-base status due to decreased solute clearance and decreased glomerular filtration rate (GFR) (urine <0.5 ml/kg/hr for >6 hrs). In critically ill patients the dilution of SCr by fluid accumulation may lead to underestimation of the severity of AKI and delayed diagnosis of AKI (4).

Background: Acute Kidney Injury (AKI) is an unsolved clinical problem in critical care patients with a high mortality rate, increasing incidence, and no definitive therapy. We studied the incidence, risk factors, and mortality associated with AKI in ICU patients.

Materials and Methods: In a prospective study, patient demographics, reason for hospitalization, reason for ICU admission, Length of ICU stay, laboratory data, and Vital signs were recorded in prepared forms during the ICU stay. AKI was defined as an increase in serum creatinine (SCr) of ≥ 0.3mg/dl from the baseline.

Results: A total of 200 patients who were enrolled in our study; 134 (67%) did not develop AKI during their ICU stay while 66 (33%) developed AKI (SCr ≥ 0.3) according to the AKIN definition. Patients with AKI had higher APACHE II scores (12.3±5.6 vs. 6.9±3.6; P< 0.001), longer ICU stays (7.6±7.6 vs. 3.7±2.8 days respectively; P< 0.001), and higher mortality (19.7% vs. 0.7%; P< 0.001).

Conclusion: The AKIN criteria are clinically valid and can be a good predictor of mortality and patient outcome in addition to APACHE II score in ICU patients.

Key words: Acute kidney injury, Intensive care unit, Glomerular filtration rate
Oliguria is common in ICU patients and might be better in identifying patients with AKI compared to serum creatinine criterion (5). There is an association between AKI and patient outcomes. However, associated organ failure had a greater impact on prognosis than severity of AKI (6). 5-7% of the hospitalized patients and 30% of ICU patients develop AKI (7). Although risk factors for AKI are not fully understood, it has severe consequences (8). The reported mortality rate associated with AKI is 20-90%, which has not changed significantly over the last 15 years. Mortality rate depends on the patient’s general condition, age, and the severity of illness. Among patients who are admitted to the ICU because of AKI, older patients experience higher rates of AKI. There used to be no uniform definition of AKI in the literature until the Acute Kidney Injury Network (AKIN) developed a new definition based on scientific investigation (9). As minor increases in serum creatinine (≥0.3mg/dl) are associated with increased mortality, AKIN chose changes in SCr as the basis of their definition of AKI (10). Besides mortality, AKI increases other morbidities, which are associated with increased costs (11), increased length of hospital stay (12,13), and increased risk of developing chronic kidney disease (CKD), including end-stage kidney disease (14-17).

Despite available evidence about the impact of AKI on morbidity and mortality, there are inadequate data on epidemiology and outcomes associated with AKI in different parts of the world. Besides, the definition of AKI needs to be validated in order to accurately predict patient outcome. As more studies are conducted our understanding of the disease, its risk factors, and associated mortality will improve. In the current study we investigated the incidence, risk factors, and mortality associated with AKI in the ICU population.

**MATERIALS AND METHODS**

**Study Design**

We conducted a prospective observational study from Feb 2010 to Aug 2010 in our tertiary referral center. All study protocols were reviewed and approved by the institutional ethics committee of National Research Institute of Tuberculosis and Lung diseases (NRITLD), Shahid Beheshti University of Medical Sciences. Informed consent was obtained from patients or their legal surrogates and all patient information were kept confidential. Patient demographics, reason for hospital admission, reason for ICU admission, length of ICU stay, laboratory data, and vital signs were recorded during their ICU stay. Vital signs included heart rate, respiratory rate, blood pressure, and Glasgow Coma Scale score.

Datasheets were completed by a physician who was blinded to the study to reduce the possibility of bias. Statistical analysis was carried out by a statistician who was blinded to the study design as well. Daily visits were carried out by attending intensivists. All physical examinations prior to admission and during the ICU stay were performed by the attending intensivist. As comorbidities are important in predicting mortality, all co-morbidities including cardiovascular diseases, gout, cirrhosis, glomerulonephritis or any other kidney disease such as chronic kidney disease were recorded. Other conditions which could potentially predispose patients to kidney injury, such as hemorrhage, diarrhea, vomiting, hyperthermia or fever, and administration of nephrotoxic agents were recorded. We adjusted drug doses based on the patients’ kidney function. The amount of urine produced by each patient was measured hourly. Laboratory tests including electrolytes, blood urea nitrogen and serum creatinine were measured at baseline (before admission), at 6 AM every day during ICU stay, when AKI was diagnosed, and at 24 and 48 hours after AKI was diagnosed. The ability of AKIN criteria for predicting hospital mortality was compared to that of the APACHE II score, age, and multi-organ failure.

**Patient Selection**

Acute kidney injury was defined as an increase in serum creatinine (SCr) of ≥ 0.3mg/dl from the baseline. The lowest value of SCr during the ICU stay or within 24 hours before admission was considered the baseline SCr. Patients were categorized into two groups: AKI and Non-
AKI. The patients in the AKI group had an increase in SCr of ≥ 0.3 mg/dL during their ICU stay as previously specified. Intensive care unit mortality, length of ICU stay, and renal replacement therapy (RRT) use were compared between the two groups.

**Statistical analysis**

Statistical analysis was performed using SPSS version 16 (SPSS Inc., Chicago, IL). All continuous data are presented as mean ± SD. Student’s t-test was applied to compare normally distributed means. Chi-squared or Fisher’s exact tests were used to compare discrete variables. Univariate logistic regression was used in order to demonstrate AKI as an independent predictor of hospital mortality. Multivariate analysis was performed in order to evaluate the predictive value of variables on mortality and LOS. The cut-off point for LOS was 5 days (the 75% percentile of all LOS). The means of continuous independent variables were used as cut-off points in logistic regression analysis. Variables with significant association to patient outcomes in univariate analysis were used in the regression analysis. Maximizing the Youden index was also used to find the best cut-off points for age and APACHE II score in comparison of predictors. A P-value < 0.05 was considered statistically significant.

**RESULTS**

Of the 200 patients who were enrolled in our study 66 (33%) developed AKI according to the AKIN definition (SCr increase ≥ 0.3). The mean age of the patients in the non-AKI group, and that of the patients in the AKI group were 43.9±18.7 and 54.5±19.1 years, respectively (p <0.001). Seventy-six (56.7%) patients in the non-AKI group and 38 (57.6%) in the AKI group were men. Patient demographic data, diagnoses, and referring services are shown in tables 1 and 2. Patients who developed AKI had higher APACHE II scores (12.3±5.6 vs. 6.9±3.6; P< 0.001), longer ICU stays (7.6±7.6 vs. 3.7±2.8 days respectively; P< 0.001), and higher mortality rates (19.7% vs. 0.7%; P< 0.001). Mortality rate in patients with AKI was 13 times higher than that of those who did not develop AKI. Also the number of days on mechanical ventilation, duration of vasoactive drug infusions, and duration of dobutamine infusion were longer in the patients who developed AKI compared to those who did not develop AKI. (P< 0.001; P=0.007). Serum creatinine clearance before admission to ICU was 0.91±0.26 in the non-AKI patients and 0.93±0.3 in those who developed AKI (P=0.654). APACHE II scores were significantly different between the two groups (6.86±3.6 in non-AKI vs. 12.3±5.6 in AKI; P<0.001). Acute kidney injury was a significant predictor of mortality after adjusting for other comorbidities in the multivariate logistic regression. Our data revealed that AKI patients had a higher rate of complications (54% vs. 23%; P=0.012) and multi organ failure (43% vs.12%; P=0.031) (Tables 3 and 4).

Age, APACHE II score, AKI, and dobutamine use were independent predictors of mortality. Development of AKI was the strongest predictor of mortality after adjusting for all other variables in the multiple logistic regression analysis (OR adjusted=14.8; 95%CI: 1.8-121.98) and had the same sensitivity as APACHE II score for predicting mortality (Sensitivity = 0.93). Median length of ICU stay was 5 days for the AKI group and 3 days for the non-AKI group (p=0.001).

We did not find a significant difference between LOS in dead and alive patients in the AKI group. Multivariate logistic regression analysis showed that AKI is a powerful predictor of LOS. Acute kidney injury, defined according to the AKIN criteria, can predict mortality with 71% specificity and 93% sensitivity. APACHE II score can predict ICU mortality with 75% specificity and 93% sensitivity, while age and dobutamine use had a lower sensitivities (0.57 vs. 0.21) compared to those of AKI and APACHE II score. AKIN criteria and APACHE II score are equally good predictors of ICU mortality. Youden index for these two criteria are 0.64 and 0.68 respectively. Youden index for age and dobutamine use are 0.21 and 0.18, respectively, which are considered weak.
Table 1. Patient demographic and clinical characteristics of patients with AKI vs. those who did not develop AKI. Relative risk of mortality stratified across demographic and clinical variables.

|                          | Total      | Non-AKI    | AKI        | RR  | 95% CI | P Value |
|--------------------------|------------|------------|------------|-----|--------|---------|
| **Frequency, n(%)**      | 200(100)   | 134(67)    | 66(33)     |     |        | NA      |
| **Age, yrs**             |            |            |            |     |        |         |
| Mean ± SD                | 47.42±19.4 | 43.9±18.7  | 54.5±19.1  | 2.4 | 1.3-3.88 | <0.0001 |
| Median (IQR)             | 49(30.25-64)| 45(26-60)  | 58(44.7-70.25) |   |        | <0.0001 |
| **Gender**               |            |            |            |     |        |         |
| Male, n(%)               | 114(57)    | 76(56.7)   | 38(57.6)   | 2.7 | 0.9-4.7 | 0.908   |
| Female, n(%)             | 86(43)     | 58(43.3)   | 28(42.4)   | 1.5 | 0.5-3.3 | 0.908   |
| **APACHE II**            |            |            |            |     |        |         |
| Mean ± SD                | 8.65±5.02  | 6.86±3.6   | 12.3±5.6   | 7.2 | 3.49-25.6 | <0.0001 |
| Median (IQR)             | 8(5-11.75) | 7(4-9)     | 12(8-17)   |     |        | <0.0001 |
| **First SCr**            |            |            |            |     |        |         |
| Mean ± SD                | 0.91±0.28  | 0.9±0.26   | 0.93±0.3   | 2.7 | 1.1-3.8 | 0.654   |
| Median (IQR)             | 0.9(0.7-1.1)| 0.9(0.77-1.1)| 0.8(0.7-1.2) |   |        | 0.960   |
| **LOS**                  |            |            |            |     |        |         |
| Mean ± SD                | 5±5.2      | 3.7±2.8    | 7.6±7.6    | 1.76 | 0.9-2.8 | <0.0001 |
| Median (IQR)             | 3(2-5)     | 3(2-4)     | 5(3-8.25)  |     |        | <0.0001 |
| **MVD**                  |            |            |            |     |        |         |
| Mean ± SD                | 1.31±3.6   | 0.38±1.1   | 3.2±5.6    | 2.28 | 0.88-3.96 | <0.0001 |
| Median (IQR)             | 0(0-1)     | 0(0-0)     | 1(0-3.25)  |     |        | <0.0001 |
| **Time of vasocactives** |            |            |            |     |        |         |
| Mean ± SD                | 0.37±1.2   | 0.14±0.6   | 0.82±1.9   | 1.23 | 0.7-1.67 | 0.007   |
| Median (IQR)             | 0(0-0)     | 0(0-0)     | 0(0-1)     |     |        | <0.0001 |
| **Dobutamin n (%)**      | 9(4.5)     | 2(1.5)     | 7(10.6)    | 3.45 | 1.7-5.45 | 0.007   |
| **Mortality n (%)**      | 14(7)      | 10(7)      | 13(19.7)   |     |        | <0.0001 |

AKI: acute kidney injury; APACHE: Acute Physiology and Chronic Health Evaluation; SCr: Serum Creatinine; LOS: Length of Stay; MVD: Mechanical Ventilation Duration.

Table 2. Main diagnosis for hospitalization and the referring services in AKI and Non-AKI groups

| Diagnosis               | Total     | Non-AKI   | AKI       |
|-------------------------|-----------|-----------|-----------|
| COPD                    | 19(9.5)   | 9(6.7)    | 10(15.2)  |
| Empyema                 | 5(2.5)    | 3(2.2)    | 2(3)      |
| Pulmonary emboli        | 13(6.5)   | 10(7.5)   | 3(4.5)    |
| Hemothorax/pneumothorax | 3(1.5)    | 3(2.2)    | 0(0)      |
| Sleep apnea             | 3(1.5)    | 2(1.5)    | 1(1.5)    |
| CABG                    | 27(13.5)  | 14(10.4)  | 13(19.7)  |
| PNET                    | 1(0.5)    | 1(0.7)    | 0(0)      |
| MVR                     | 6(3)      | 2(1.5)    | 4(6.1)    |
| Hydatid cyst            | 22(11)    | 20(14.9)  | 2(3)      |
| Pneumonia               | 7(3.5)    | 1(0.7)    | 6(9.1)    |
| Mesothelioma            | 3(1.5)    | 3(2.2)    | 0(0)      |
| Tracheal Stenosis       | 25(12.5)  | 22(16.4)  | 3(4.5)    |
| Hemoptysis              | 7(3.5)    | 6(4.5)    | 1(1.5)    |
| TB                      | 5(2.5)    | 3(2.2)    | 2(3)      |
| Esophagael Problem      | 3(1.5)    | 2(1.5)    | 1(1.5)    |
| Cancer                  | 12(6)     | 7(5.2)    | 5(7.6)    |
| Asthma                  | 1(0.5)    | 1(0.7)    | 0(0)      |
| Tumors                  | 13(6.5)   | 10(7.5)   | 3(4.5)    |
| Others                  | 25(12.5)  | 15(11.2)  | 10(15.2)  |

Referrer groups

| Diagnosis | Total     | Non-AKI   | AKI       |
|-----------|-----------|-----------|-----------|
| Internal  | 59(29.5)  | 30(22.4)  | 29(43.9)  |
| Surgery   | 102(51)   | 84(62.7)  | 18(27.3)  |
| Heart     | 39(19.5)  | 20(14.9)  | 19(28.8)  |

PNET: Primitive neuroectodermal tumors, MVR: Mitral valve regurgitation, TB: Tuberculosis; CABG: Coronary artery bypass graft.

Tanaffos 2016; 15(2): 89-95
Table 3. Predictors of ICU mortality and length of stay in patients with AKI - Univariate and Multivariate Analysis

| Predictors | Mortality | LOS |
|------------|----------|-----|
|            | Relative risk | 95% CI | Relative risk | 95% CI |
| **Univariate analysis** | | | |
| Age >48 | 1.58 | 0.51-4.899 | 2.508 | 1.351-4.656 |
| APACHE > 9 | 27.3 | 3.49-213.56 | 1.866 | 0.808-3.412 |
| AKI | 32.6 | 4.16-255.6 | 3.987 | 2.125-7.481 |
| Dobutamin | 8.182 | 1.801-37.174 | 4.262 | 1.031-17.614 |
| **Multivariate Logistic Regression** | | | Standard error |
| APACHE > 9 | 12.7 | 1.53-104.9 | 0.8 | 0.742 |
| AKI | 14.8 | 1.8-121.98 | 1.21 | 0.808 |
| Dobutamin | 3.412 | 0.591-19.7 | 3.28 | 0.796 |

CI, confidence interval; AKI, Acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation.

Table 4. Comparative Predictors of Mortality

| Total | Mortality% | Sensitivity | Specificity | Youden indexa | PPV | NPV | Accuracyb |
|-------|-------------|-------------|-------------|---------------|-----|-----|-----------|
| Age≥55.5 | 76 | 10% | 0.57 | 0.63 | 0.21 | 0.10 | 0.95 | 0.63 |
| APACHE ≥10.5 | 59 | 22% | 0.93 | 0.75 | 0.68 | 0.22 | 0.99 | 0.76 |
| AKI | 66 | 20% | 0.93 | 0.71 | 0.64 | 0.20 | 0.99 | 0.73 |
| Dobutamin | 9 | 33% | 0.21 | 0.97 | 0.18 | 0.33 | 0.94 | 0.90 |

PPV, Positive predictive value; NPV, Negative predictive value; APACHE, Acute Physiology and Chronic Health Evaluation; AKI, Acute Kidney Injury.

aYouden index = sensitivity+Specificity – 1 ; bAccuracy = (true results/ all results)

**DISCUSSION**

The purpose of this study was to investigate the outcomes associated with AKI in ICU patients and to determine the predictors of mortality in patients who develop AKI during their ICU stay in a prospective observational study, using the AKIN criteria to diagnose AKI. Oliguria lasting for more than 12 hours and ≥ 3 more episodes of oliguria are associated with increased mortality and are sensitive markers for AKI and are associated with adverse outcomes in ICU patients (18). Previously RIFLE criteria were used to diagnose kidney injury (19). However, newer evidence suggests that smaller rises in SCr (≥ 0.3 mg/dL) should be used to diagnose kidney injury (20). A simplified definition of AKI which uses elevations in SCr is more helpful and advantageous than hourly measurements urine output and is able to predict patient outcomes more accurately.

Our findings show that patients who have met the AKIN criteria for AKI had higher ICU morbidity and mortality. In addition, patients who developed AKI had significantly longer hospital stays and required RRT more than those who did not develop AKI. Using other definitions for acute renal failure, previous studies have demonstrated that mortality and hospital length of stay was significantly higher in patients who developed acute renal failure during their ICU stay (19, 21). These investigators used different diagnostic criteria and definitions for AKI (more than 20 different definitions) and found incidence of AKI to be more than 50% in ICU patients. In those studies RRT was an accurate predictor. Patients who needed RRT had longer hospital stays and higher mortality (50%>70%). In our study, average ICU mortality during the study period was 7% but this rate was 19.8% in patients who developed AKI. Barrantes et al. (9)
and Uchino et al. (14) found higher mortality rates in their studies (39% and 60% respectively). Barrantes et al. (9) used the AKIN criteria while Uchino et al. used different criteria to diagnose AKI; they defined acute renal failure as need for RRT, BUN > 84 mg/dL or a decrease in urine output (<200 ml/12 hrs). Both studies had a greater sample size compared to our study. Comparing our results with those from other studies that used different criteria is difficult and emphasizes the need for a uniform definition for AKI, which can accurately predict patient outcomes. The relationship between AKI and mortality in ICU was significant in our study (odds ratio 3.99; 95% CI 2.125–7.481), which is consistent with findings from other studies (22). We found a strong association between AKI and mortality with a high sensitivity (93%), while Barrantes et al. reported a lower sensitivity (56%). This disagreement may be the result of different study designs (prospective vs. retrospective). Similar to our findings, Barrantes et al. reported 77% specificity (71% in our study). This yielded a Youden index of 0.64 for our study in comparison to a Youden index of 0.33 in Barrante’s study. High sensitivity and specificity, as well as high Youden index make AKIN criteria for AKI highly predictive of ICU mortality.

Our study had several limitations including small sample size from a single center, even though we tried to include a broad range of ICU patients (post surgical patients, patients with coronary disease, and those with respiratory complications, etc.) as detailed in Table 2. Moreover, we excluded patients with pre-existing kidney complications. Additionally, we selected patients with normal baseline SCr. It is unclear whether baseline SCr levels affect patient outcomes or not.

In conclusion, we investigated AKIN criteria for AKI as predictor of ICU mortality and demonstrated that AKIN criteria is clinically valid and can be a good predictor of mortality and patient outcomes in addition to APACHE II score in ICU patients. Future studies with larger sample sizes are needed to confirm our findings and validate AKIN criteria for AKI. These indexes help patients at risk of AKI receive closer attention and perhaps have better outcomes.

REFERENCES

1. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. *Am J Nephrol* 2012;35(4):349-55.

2. Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, et al. Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. *Clin J Am Soc Nephrol* 2012;7(5):856-60.

3. Demirjian S, Chertow GM, Zhang JH, O'Connor TZ, Vitale J, Paganini EP, et al. Model to predict mortality in critically ill adults with acute kidney injury. *Clin J Am Soc Nephrol* 2011;6(9):2114-20.

4. Macedo E, Bouchard J, Soroko SH, Chertow GM, Himmelfarb J, Ikizler TA, et al. Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. *Crit Care* 2010;14(3):R82.

5. Macedo E, Malhotra R, Claure-Del Granado R, Fedullo P, Mehta RL. Defining urine output criterion for acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 2011;26(2):509-15.

6. Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. *Crit Care Med* 2007;35(8):1837-43; quiz 1852.

7. Joannidis M, Druml W, Forni LG, Groeneveld AB, Honore P, Oudemans-van Straaten HM, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. *Intensive Care Med* 2010;36(3):392-411.

8. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11(2):R31.

9. Barrantes F, Feng Y, Ivanov O, Yalamanchili HB, Patel J, Buenafe X, et al. Acute kidney injury predicts outcomes of non-critically ill patients. *Mayo Clin Proc* 2009;84(5):410-6.
10. Tian J, Barrantes F, Amoateng-Adjepong Y, Manthous CA. Rapid reversal of acute kidney injury and hospital outcomes: a retrospective cohort study. Am J Kidney Dis 2009;53(6):974-81.

11. Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, et al. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med 2011;39(6):1493-9.

12. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006;17(4):1135-42.

13. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10(3):R73.

14. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294(7):813-8.

15. Liaño F, Felipe C, Tenorio MT, Rivera M, Abraira V, Sáez-de-Urturi JM, et al. Long-term outcome of acute tubular necrosis: a contribution to its natural history. Kidney Int 2007;71(7):679-86.

16. Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005;9(6):R700-9.

17. Morgera S, Kraft AK, Siebert G, Luft FC, Neumayer HH. Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. Am J Kidney Dis 2002;40(2):275-9.

18. Macedo E, Malhotra R, Bouchard J, Wynn SK, Mehta RL. Oliguria is an early predictor of higher mortality in critically ill patients. Kidney Int 2011;80(7):760-7.

19. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006;34(7):1913-7.

20. Claure-Del Granado R, Macedo E, Chertow GM, Soroko S, Himmelfarb J, Ikizler TA, et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin J Am Soc Nephrol 2011;6(3):467-75.

21. Bouman C, Kellum JA, Lamiere N, et al. Definition for acute renal failure. Acute Dialysis Quality Initiative Web site. http://www.ccm.upmc.edu/adqi/ADQI2/ADQI2g1.pdf. Accessed April 9, 2007

22. Macedo E, Zanetta DM, Abdulkader RC. Long-term follow-up of patients after acute kidney injury: patterns of renal functional recovery. PLoS One 2012;7(5):e36388.